Showing 6501-6510 of 10001 results for "".
- Positive 90-Day Results from CONFORM Study: Recros Medicahttps://practicaldermatology.com/news/positive-90-day-results-from-conform-study-recros-medica/2460042/Ninety-day results from the CONFORM study assessing the efficacy, safety, and patient satisfaction of the Rotational Fractional Resection (RFR) procedure for submental contouring are promising. RFR is a novel, proprietary alternative to traditional approaches to treat skin laxity developed by
- Sensus Healthcare Awarded Brachytherapy Products Agreement with Premierhttps://practicaldermatology.com/news/sensus-healthcare-awarded-brachytherapy-products-agreement-with-premier/2460025/Sensus Healthcare, Inc.has been awarded a group purchasing agreement for Brachytherapy Products with Premier. Effective August 1, 2019, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Sensus’ SRT-100
- Aesthetic Innovations Summit Coming to New Orleanshttps://practicaldermatology.com/news/aesthetic-innovations-summit-coming-to-new-orleans/2460022/Coming off an impressive inaugural meeting in 2018, the second annual Aesthetics Innovation Summit will unite over 300 of the most influential corporate, capital, and clinical leaders in New Orleans to collaborate on the development and adoption of new aesthetic treatments and technologies.
- SkinBioTherapeutics Names New Executive Directorhttps://practicaldermatology.com/news/skinbiotherapeutics-names-new-executive-director/2460012/Stuart Ashman is the new executive director of SkinBioTherapeutics. Mr. Ashman will succeed Professor Cath O’Neill as CEO after a period of transition. Ms. O’Neill will continue to drive the science and the ongoing commercial
- FDA Approves AbbVie's Skyrizi for Psoriasishttps://practicaldermatology.com/news/fda-approves-abbvies-skyrizi-for-psoriasis/2460007/Skyrizi™ (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In clinical trials, Skyrizi prod
- L'Oreal To Support Reconstruction of Notre Dame Cathedralhttps://practicaldermatology.com/news/loreal-to-support-reconstruction-of-notre-dame-cathedral/2460003/The Bettencourt Meyers family and the L’Oréal Group are making a joint donation of 100 million euros toward the “renaissance” of the Notre-Dame Cathedral, which they describe as a symbol of French heritage and common history.
- InMode Launches AccuTite, the Smallest RFAL Treatment for Face and Bodyhttps://practicaldermatology.com/news/inmode-launches-accutite-the-smallest-rfal-treatment-for-face-and-body/2460000/InMode Ltd
- American Skin Association Names Almirall Distinguished Corporate Leaderhttps://practicaldermatology.com/news/american-skin-association-names-almirall-distinguished-corporate-leader/2459997/Almirall took home the Distinguished Corporate Leadership award by the American Skin Associ
- Allergan 360° Aesthetics Report Shines Light on Evolving Beauty Perceptions Around the Worldhttps://practicaldermatology.com/news/allergan-3600-aesthetics-report-shines-light-on-evolving-beauty-perceptions-around-the-world/2459994/The digital boom and millennials are growing the aesthetics category, and wellness and self-care are the new key drivers, according to the Allergan 360° Aesthetics Report. To develop the report, Allergan tapped into more than 14,500
- Derm Students Improve Wikipedia Entries on Skin Disease, Boost Viewshttps://practicaldermatology.com/news/derm-students-improve-wikipedia-entries-on-skin-disease-boost-views-1/2459992/A group of medical students recruited to improve Wikipedia articles on skin-related diseases and saw millions more views of those stories following their editing, a new study shows. "We tried to make the articles more readable, while adding more relevant information," say